India's Zydus Life agrees $120 million settlement with Astellas over bladder drug

Core Viewpoint - Zydus Lifesciences and its U.S. unit will pay $120 million to Astellas Pharma to settle a patent dispute regarding the bladder disorder drug Mirabegron, allowing Zydus to continue marketing its generic version in the U.S. [1][2] Group 1 - The settlement includes a pre-paid per-unit licensing fee on sales of Zydus's generic Mirabegron in the U.S. until September 2027 [1] - Following the announcement, shares of Zydus increased by as much as 1.3% [2] - The deal comes shortly after Lupin, a local competitor, settled a similar dispute with Astellas for $90 million [2] Group 2 - Analysts from Citi indicated that the settlement could delay the entry of other generic competitors in the U.S. market, potentially providing Zydus and Lupin with a period of limited competition [3]